Navigation Links
New Mobile STAR Cranial Center of Excellence Vehicle Brings Cutting-Edge Treatment to Satellite Communities
Date:9/10/2009

DALLAS, Sept. 10 /PRNewswire/ -- Orthomerica Products Inc. is taking its high tech treatment for cranial remolding on the road with the company's new Mobile STAR Cranial Center of Excellence, a vehicle equipped with the company's STARscanner -- a head shape scanning system that scans a child's head in less than two seconds. The vehicle's scanner can be easily moved for use in satellite clinics wherever the unit travels, and the van is also equipped with the necessary tools to make adjustments to STARband cranial remolding helmets.

The Mobile STAR Cranial Center of Excellence will be based at the company's Dallas STAR Cranial Center of Excellence location and will travel to satellite communities that do not normally have access to this industry-leading cranial remolding technology.

"This vehicle will allow our practitioners to travel around the Dallas metro area in an effort to increase awareness for plagiocephaly and other head shape abnormalities, and to educate pediatricians, practitioners and families of the importance of early recognition," said Bill Gustavson, Director of Operations for STAR Cranial Center of Excellence. "But more importantly, it allows us to use our STAR Cranial Center of Excellence technology, tools and expert clinical staff to reach outlying communities who otherwise would not have access to the STARscanner and STARband treatment. The mobile unit also allows us to offer some follow-up appointments in those areas so families will not have to travel to Dallas every two weeks for the duration of their child's treatment."

The Mobile STAR Cranial Center of Excellence currently visits the Louisiana State University Health Sciences Center - Shreveport, Department of Oral & Maxillofacial Surgery Clinic in Shreveport, Louisiana with Dr. Ghali Ghali once per month to see patients for STARband treatment.

'/>"/>

SOURCE Orthomerica Products, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. CONCERTA(R) (methylphenidate HCl) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS
2. CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS
3. Nurses Facing National Shortage Turn to Mobile Technology to Support Patient Care
4. Choco Milk Initiates Adventure-Filled Mobile Tour That Teaches Children Nutrition Awareness
5. Dont Miss Twinlabs(R) 2009 Mobile Beach Bash Grand Finale Celebration Labor Day Weekend
6. Mom & Baby Mobile Health Centers Have Become Primary Care Providers Along the Gulf Coast
7. Mobile MedCheck Brings Back House Calls
8. Lagan Increases Productivity of Case Management Workers in the Field; Saves Time and Money for Human Services Agencies with Lagan Mobile(TM)
9. Ingenious Meds IM Quality(TM) Solution Goes Mobile
10. Verizon Wireless Offers Healthy Applications to Turn a Mobile Phone Into a Personal Trainer
11. ASAP Systems Introduces Mobile RFID Technology for its Passport Assets Application Enabling Increase Asset Management Flexibility
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Moravia Worldwide to Present Live Webinar on Creation and Use of Terminology in Localization 2Health News:Moravia Worldwide to Present Live Webinar on Creation and Use of Terminology in Localization 3Health News:Lung Cancer Alliance Praises Growing National Coalition 2Health News:Lung Cancer Alliance Praises Growing National Coalition 3Health News:Book Offers Help for Parents Struggling with Difficult Teens During the Upcoming Holidays 2Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 2Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 3Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 4Health News:Procter & Gamble Announces Appointment of Director 2
Breaking Medicine Technology:Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 2Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 3Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 4Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 5Top 5 Global Spinal Implant Companies Maintaining Position but Competition Rising Rapidly 2Top 5 Global Spinal Implant Companies Maintaining Position but Competition Rising Rapidly 3Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 2Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 3Wasting Millions on Purchases Based on Physician Preference White Paper Now Available From ECRI Institute 54884 1Wasting Millions on Purchases Based on Physician Preference White Paper Now Available From ECRI Institute 54884 2Wasting Millions on Purchases Based on Physician Preference White Paper Now Available From ECRI Institute 54884 3Reliv Walk for the Mission Raises Approximately 2447 000 for Malnourished People 54882 1Reliv Walk for the Mission Raises Approximately 2447 000 for Malnourished People 54882 2N2Care Unveils Backyard Smart MEDcottage 54880 1N2Care Unveils Backyard Smart MEDcottage 54880 2
Other Medicine Technology:Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 2Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 3Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 4Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 5Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 6Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 7Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year 2Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year 3Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year 4